$329 Million is the total value of Krensavage Asset Management, LLC's 15 reported holdings in Q2 2017. The portfolio turnover from Q1 2017 to Q2 2017 was 13.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Sell | BIOVERATIV INC | $42,646,000 | +4.9% | 708,754 | -5.0% | 12.95% | -1.2% | |
| ENTA | Buy | ENANTA PHARMACEUTICALS INC | $39,758,000 | +17.5% | 1,104,992 | +0.6% | 12.07% | +10.6% |
| GILD | Sell | GILEAD SCIENCES INC | $37,686,000 | +3.3% | 532,434 | -0.9% | 11.44% | -2.7% |
| UTHR | Buy | UNITED THERAPEUTICS CORP | $35,416,000 | +11.4% | 272,996 | +16.3% | 10.75% | +4.9% |
| SCMP | Buy | SUCAMPO PHARMACEUTICALS-CL A | $29,607,000 | -4.0% | 2,819,708 | +0.6% | 8.99% | -9.6% |
| OFIX | Sell | ORTHOFIX INTERNATIONAL NV | $27,135,000 | +2.0% | 583,807 | -16.3% | 8.24% | -4.0% |
| RTIX | Buy | RTI SURGICAL INC | $26,121,000 | +47.1% | 4,465,086 | +0.6% | 7.93% | +38.5% |
| MRK | Sell | MERCK & CO. INC. | $24,510,000 | +0.2% | 382,434 | -0.6% | 7.44% | -5.6% |
| HYH | Sell | HALYARD HEALTH INC | $22,427,000 | +0.7% | 570,964 | -2.3% | 6.81% | -5.2% |
| IVC | Sell | INVACARE CORP | $14,798,000 | +8.1% | 1,121,066 | -2.6% | 4.49% | +1.7% |
| UNIS | New | AMGEN INC | $13,275,000 | – | 77,079 | +100.0% | 4.03% | – |
| CNMD | Sell | CONMED CORP | $11,538,000 | -27.1% | 226,497 | -36.4% | 3.50% | -31.4% |
| AVIR | AVIRAGEN THERAPEUTICS INC | $1,899,000 | +2.8% | 2,836,326 | 0.0% | 0.58% | -3.2% | |
| DRAD | DIGIRAD CORP | $1,353,000 | -23.6% | 334,179 | 0.0% | 0.41% | -28.0% | |
| JNP | JUNIPER PHARMACEUTICALS INC | $1,228,000 | +6.3% | 243,128 | 0.0% | 0.37% | +0.3% | |
| AMGN | Exit | AMGEN INC | $0 | – | -68,015 | -100.0% | -3.60% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITED THERAPEUTICS CORP | 36 | Q3 2023 | 18.1% |
| Enanta Pharmceuticals Inc | 35 | Q3 2023 | 16.7% |
| INVACARE CORP | 28 | Q3 2021 | 5.8% |
| RTI SURGICAL INC | 23 | Q2 2020 | 7.9% |
| MCKESSON CORP | 20 | Q3 2022 | 16.3% |
| BIOGEN INC | 19 | Q3 2023 | 16.0% |
| MERCK & CO. INC. | 18 | Q1 2019 | 11.1% |
| DIGIRAD CORP | 18 | Q1 2019 | 1.0% |
| REGENERON PHARMACEUTICALS | 16 | Q3 2023 | 16.1% |
| ALKERMES PLC | 16 | Q3 2023 | 14.1% |
View Krensavage Asset Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| SURGALIGN HOLDINGS, INC. | February 19, 2021 | 5,380,449 | 6.6% |
| RTI SURGICAL, INC. | February 14, 2019 | 3,852,567 | 6.1% |
| Aviragen Therapeutics, Inc. | February 15, 2018 | 2,292,058 | 5.9% |
| ENANTA PHARMACEUTICALS INC | February 15, 2017 | 883,902 | 4.6% |
| Biota Pharmaceuticals, Inc. | February 17, 2016 | 2,267,655 | 5.9% |
View Krensavage Asset Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SCHEDULE 13G | 2024-02-27 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-15 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-16 |
| 13F-HR | 2023-02-15 |
| 13F-HR | 2022-11-15 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-17 |
| 13F-HR | 2022-02-15 |
View Krensavage Asset Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.